Par Pharmaceuticals (PRX): Upgraded to Overweight at Barclays; target raised to $30
Tweet Send to a Friend
From Notable Calls:
Barclays is upgrading Par Pharmaceuticals (NYSE: PRX) to Overweight from Equal Weight with a $30 target (prev ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays is upgrading Par Pharmaceuticals (NYSE: PRX) to Overweight from Equal Weight with a $30 target (prev ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
